Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1034702 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK1034702 | EXPERIMENTAL | Single oral 5 mg dose in liquid formulation |
| Cohort 1 | OTHER | Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan |
| Cohort 2 | OTHER | Subjects will be receive GSK1034702 5 mg following the dose escalation plan |
| Name | Type | Description |
|---|---|---|
| GSK1034702 | DRUG | Single oral 5 mg dose in liquid formulation |
| Placebo | DRUG | To match GSK1034702 |
Inclusion Criteria: * Generally healthy. * Male between 35 and 55 years of age. * Willing to use appropriate contraception method. * Weight more than 50 kg. * BMI within the range 19 - 29 kg/m2. * Adequate blood supply to the hand. Exclusion Criteria: * Abuse of drugs or alcohol. * Smoker or hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-101 |
| Eli Lilly and Company | LLY | 2 | - | Undisclosed |
| Rhythm Pharmaceuticals, Inc. | RYTM | 1 | - | Undisclosed |
GSK1034702 is an investigational small molecule being developed for cognitive disorders. It is a Phase 1 candidate that has been studied in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetics, as well as its brain uptake using PET imaging. It is not yet approved and remains in clinical development.
GSK1034702 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company has sponsored two Phase 1 clinical trials for this candidate, both of which have been completed.
GSK1034702 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 34 participants enrolled. The drug is investigational and has not been approved by regulatory authorities for any use.
GSK1034702 has been studied in two completed Phase 1 trials. NCT00743405 evaluated safety, tolerability, and pharmacokinetics in 30 healthy subjects in the United Kingdom. NCT00937846 assessed brain uptake via PET scanning in 4 healthy male volunteers aged 35 years and older.
No alternative names for GSK1034702 have been identified. The drug is referred to solely by its development code GSK1034702 in the clinical trial records and is not known to be marketed under any other name.